367 related articles for article (PubMed ID: 27565926)
1. Severe agranulocytosis in a patient with metastatic non-small-cell lung cancer treated with nivolumab.
Tabchi S; Weng X; Blais N
Lung Cancer; 2016 Sep; 99():123-6. PubMed ID: 27565926
[TBL] [Abstract][Full Text] [Related]
2. Development of psoriatic arthritis during nivolumab therapy for metastatic non-small cell lung cancer, clinical outcome analysis and review of the literature.
Ruiz-Bañobre J; Pérez-Pampín E; García-González J; Gómez-Caamaño A; Barón-Duarte FJ; López-López R; Vázquez-Rivera F
Lung Cancer; 2017 Jun; 108():217-221. PubMed ID: 28625638
[TBL] [Abstract][Full Text] [Related]
3. A pilot trial of nivolumab treatment for advanced non-small cell lung cancer patients with mild idiopathic interstitial pneumonia.
Fujimoto D; Morimoto T; Ito J; Sato Y; Ito M; Teraoka S; Otsuka K; Nagata K; Nakagawa A; Tomii K
Lung Cancer; 2017 Sep; 111():1-5. PubMed ID: 28838377
[TBL] [Abstract][Full Text] [Related]
4. Isolated neutropenia as a rare but serious adverse event secondary to immune checkpoint inhibition.
Naqash AR; Appah E; Yang LV; Muzaffar M; Marie MA; Mccallen JD; Macherla S; Liles D; Walker PR
J Immunother Cancer; 2019 Jul; 7(1):169. PubMed ID: 31277704
[TBL] [Abstract][Full Text] [Related]
5. Predictive Factors of Nivolumab-induced Hypothyroidism in Patients with Non-small Cell Lung Cancer.
Maekura T; Naito M; Tahara M; Ikegami N; Kimura Y; Sonobe S; Kobayashi T; Tsuji T; Minomo S; Tamiya A; Atagi S
In Vivo; 2017; 31(5):1035-1039. PubMed ID: 28882978
[TBL] [Abstract][Full Text] [Related]
6. Coincidence of immunotherapy-associated hemophagocytic syndrome and rapid tumor regression.
Takeshita M; Anai S; Mishima S; Inoue K
Ann Oncol; 2017 Jan; 28(1):186-189. PubMed ID: 28043982
[No Abstract] [Full Text] [Related]
7. Severe nivolumab-induced pneumonitis preceding durable clinical remission in a patient with refractory, metastatic lung squamous cell cancer: a case report.
Li H; Ma W; Yoneda KY; Moore EH; Zhang Y; Pu LL; Frampton GM; Molmen M; Stephens PJ; Li T
J Hematol Oncol; 2017 Feb; 10(1):64. PubMed ID: 28245875
[TBL] [Abstract][Full Text] [Related]
8. Symptomatic leptomeningeal metastasis improvement with nivolumab in advanced non-small cell lung cancer patient.
Gion M; Remon J; Caramella C; Soria JC; Besse B
Lung Cancer; 2017 Jun; 108():72-74. PubMed ID: 28625652
[TBL] [Abstract][Full Text] [Related]
9. Treatment and relapse of interstitial lung disease in nivolumab-treated patients with non-small cell lung cancer.
Sata M; Sasaki S; Oikado K; Saito Y; Tominaga J; Sakai F; Kato T; Iwasawa T; Kenmotsu H; Kusumoto M; Baba T; Endo M; Fujiwara Y; Sugiura H; Yanagawa N; Ito Y; Sakamoto T; Ohe Y; Kuwano K
Cancer Sci; 2021 Apr; 112(4):1506-1513. PubMed ID: 33125784
[TBL] [Abstract][Full Text] [Related]
10. Bullous Pemphigoid Associated With a New Combination Checkpoint Inhibitor Immunotherapy.
Fontecilla NM; Khanna T; Bayan CY; Antonov NA; Geskin LJ
J Drugs Dermatol; 2019 Jan; 18(1):103-104. PubMed ID: 30681807
[TBL] [Abstract][Full Text] [Related]
11. A Case Report of Steroid Responsive Nivolumab-Induced Encephalitis.
Richard K; Weslow J; Porcella SL; Nanjappa S
Cancer Control; 2017; 24(5):1073274817729069. PubMed ID: 28975824
[TBL] [Abstract][Full Text] [Related]
12. Nivolumab-induced organizing pneumonitis in a patient with lung sarcomatoid carcinoma.
Gounant V; Brosseau S; Naltet C; Opsomer MA; Antoine M; Danel C; Khalil A; Cadranel J; Zalcman G
Lung Cancer; 2016 Sep; 99():162-5. PubMed ID: 27565934
[TBL] [Abstract][Full Text] [Related]
13. Immune-related pancreatitis secondary to nivolumab in a patient with recurrent lung adenocarcinoma: A case report.
Ikeuchi K; Okuma Y; Tabata T
Lung Cancer; 2016 Sep; 99():148-50. PubMed ID: 27565931
[TBL] [Abstract][Full Text] [Related]
14. Drug-induced myocarditis after nivolumab treatment in a patient with PDL1- negative squamous cell carcinoma of the lung.
Semper H; Muehlberg F; Schulz-Menger J; Allewelt M; Grohé C
Lung Cancer; 2016 Sep; 99():117-9. PubMed ID: 27565924
[TBL] [Abstract][Full Text] [Related]
15. Metastatic joint involvement or inflammatory arthritis? A conundrum with immune checkpoint inhibitor-related adverse events.
Albayda J; Bingham CO; Shah AA; Kelly RJ; Cappelli L
Rheumatology (Oxford); 2018 Apr; 57(4):760-762. PubMed ID: 29342300
[No Abstract] [Full Text] [Related]
16. Immune Thrombocytopenia Induced by Nivolumab in a Metastatic Non-Small Cell Lung Cancer Patient.
Karakas Y; Yuce D; Kılıckap S
Oncol Res Treat; 2017; 40(10):621-622. PubMed ID: 28950270
[No Abstract] [Full Text] [Related]
17. Diffuse pseudoprogression in a patient with metastatic non-small-cell lung cancer treated with Nivolumab.
Curioni-Fontecedro A; Ickenberg C; Franzen D; Rogler G; Burger IA; van den Broek M
Ann Oncol; 2017 Aug; 28(8):2040-2041. PubMed ID: 28838208
[No Abstract] [Full Text] [Related]
18. Unusual skin toxicity associated with sustained disease response induced by nivolumab in a patient with non-small cell lung cancer.
Galli G; Proto C; Cossa M; Valeri B; Sdao S; Signorelli D; Imbimbo M; de Braud F; Garassino MC; Lo Russo G
Tumori; 2019 Dec; 105(6):NP57-NP62. PubMed ID: 31456503
[TBL] [Abstract][Full Text] [Related]
19. Atezolizumab in advanced non-small-cell lung cancer.
Brower V
Lancet Oncol; 2017 Aug; 18(8):e434. PubMed ID: 28648559
[No Abstract] [Full Text] [Related]
20. The safety and efficacy of nivolumab in advanced (metastatic) non-small cell lung cancer.
Tanvetyanon T; Creelan BC; Antonia SJ
Expert Rev Anticancer Ther; 2016 Sep; 16(9):903-10. PubMed ID: 27488231
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]